Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevymis

- PMLiVE

PD-1 inhibitors shine at ASH conference

New data suggests the immunotherapy class could be also used for haematological cancers

- PMLiVE

MSD’s Kate Tillett rewarded for healthcare comms excellence

Company's external affairs director wins at Communiqué 2014

- PMLiVE

ADA: Merck launches registry for type 2 diabetes

Will collect information from 20,000 patients across four countries

- PMLiVE

Merck’s first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

Merck turns to gamification in diabetes

Working with Ayogo on mobile app to improve adherence

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

- PMLiVE

FDA backs new formulation of Noxafil

Merck wins US approval for delayed-release version of anti-infective

- PMLiVE

Merck stakes a claim to all-oral hepatitis C market

Positive data for interferon-free regimen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links